Noom Med vs Sequence 2026: GLP-1 Weight Loss Programs Compared
An in-depth comparison of Noom Med and Sequence for GLP-1 weight loss. We examine pricing, coaching models, physician oversight, medication options, and clinical evidence side-by-side to help you decide — and show where a medication-focused provider like Trimi fits in.
Written by Trimi Medical Team. Medically reviewed by Dr. Amanda Foster, MD. Our team updates competitor reviews when pricing, medication access, or program structures change so patients can compare options with current data.
Quick links: Semaglutide treatment, tirzepatide treatment, and cheapest GLP-1 injections guide.
More on GLP-1 Provider Comparisons
Noom vs Sequence for Weight Loss: What You Need to Know
If you are comparing noom vs sequence for GLP-1 weight loss, you are evaluating two of the most prominent coaching-plus-medication telehealth platforms in the market today. Noom Med pairs semaglutide prescriptions with the Noom app's behavioral psychology coaching. Sequence pairs GLP-1 medications with dedicated physician oversight from obesity medicine specialists. Both charge significantly more than medication-focused providers because they bundle premium services into the subscription price, and both position themselves as comprehensive weight management solutions rather than simple prescription platforms.
Noom Med vs Sequence, defined: Noom Med is the prescription arm of Noom, the popular calorie-tracking and behavioral change app, now expanded to include GLP-1 medications such as semaglutide and tirzepatide. Sequence is a telehealth weight loss company built around a physician-led care model, emphasizing dedicated obesity medicine specialist oversight, ongoing clinical monitoring, and premium medication management. Both are legitimate telehealth providers with licensed medical teams, but they differ substantially in their approach: Noom Med leads with behavioral coaching, while Sequence leads with physician expertise.
The central question for most patients is whether either premium model justifies its cost. Clinical trial data consistently shows that GLP-1 medication is the primary driver of weight loss outcomes. The STEP 1 trial demonstrated 14.9% body weight loss with semaglutide at 68 weeks, with both the treatment and placebo groups receiving lifestyle counseling (Wilding et al., NEJM, 2021). The medication accounted for the clinical difference, not the counseling. Patients who want the medication without paying a premium for coaching or concierge physician access may prefer a provider like Trimi, which offers semaglutide at $99 per month and tirzepatide at $125 per month with clinical oversight included.
Noom Med vs Sequence vs Trimi: Side-by-Side Comparison
| Feature | Noom Med | Sequence | Trimi |
|---|---|---|---|
| Semaglutide monthly cost | $149--$209/mo | $249--$399/mo | $99/mo |
| Tirzepatide monthly cost | Limited availability | $349--$399/mo | $125/mo |
| Additional app/coaching fee | $32--$70/mo possible | Included in price | None |
| Effective monthly total (sema) | $181--$279/mo | $249--$399/mo | $99/mo |
| Care model | App-based CBT coaching | Dedicated physician oversight | Clinical guidance |
| Medication included in price | Yes (med subscription) | Yes | Yes |
| Flat dose-independent pricing | No | No | Yes |
| Provider visits included | Yes | Yes | Yes |
| Contract commitment | Varies by plan | Varies by plan | None (month-to-month) |
| Cancellation penalties | Possible | Possible | None |
| 12-month total (semaglutide) | $2,172--$3,348 | $2,988--$4,788 | $1,188 |
| Best for | Patients who value behavioral psychology coaching alongside medication | Patients who want dedicated physician oversight from obesity specialists | Patients wanting the best value for clinical GLP-1 care |
All pricing is approximate and based on publicly available information as of April 2026. Noom Med's effective monthly total includes the potential additional Noom app subscription fee. Verify current pricing directly with each provider before enrolling.
Pricing Breakdown: What You Actually Pay
Cost is the most significant differentiator when comparing Noom Med and Sequence. Both charge materially more than medication-focused providers, but for different reasons and at different price points. Understanding the full cost picture requires looking beyond headline medication prices to capture app fees, dose escalation, and contract terms.
Noom Med Pricing
Noom Med charges $149 to $209 per month for its semaglutide medication subscription. This covers the prescription, clinical oversight, and medication delivery. However, Noom Med's behavioral coaching component often requires a separate Noom app subscription costing $32 to $70 per month depending on the plan and billing cycle. Some patients report bundled pricing that reduces the combined cost, but the total effective monthly expense for Noom Med with full coaching access typically ranges from $181 to $279 per month for semaglutide. Over twelve months, that totals $2,172 to $3,348 for medication and coaching combined. Noom Med's tirzepatide availability has been limited compared to other platforms. For a detailed look at potential side effects with this platform, see our guide on Noom Med side effects.
Sequence Pricing
Sequence is positioned at the premium end of the telehealth GLP-1 market. Semaglutide through Sequence costs approximately $249 to $399 per month, and tirzepatide ranges from $349 to $399 per month. These prices include the dedicated physician oversight, medication management, and clinical platform access that form the core of Sequence's value proposition. There is no separate coaching or app fee because physician oversight is the primary service rather than a behavioral coaching add-on. Over twelve months, Sequence's total semaglutide cost ranges from $2,988 to $4,788. For patients considering Sequence, our guide on Sequence weight loss side effects covers what to expect.
Trimi Pricing
Trimi charges $99 per month for semaglutide and $125 per month for tirzepatide. This price is flat and dose-independent, meaning you pay the same amount whether you are on a starting dose or a maintenance dose. There are no additional fees for app access, coaching, consultations, or shipping. The twelve-month total for semaglutide at Trimi is $1,188 with no risk of price escalation. Compared to Noom Med's midpoint cost of approximately $2,760 and Sequence's midpoint of approximately $3,888, Trimi saves patients $1,572 to $2,700 annually on semaglutide alone. For a broader comparison of affordable options, see our cheapest GLP-1 injections 2026 guide.
Annual Cost Perspective
GLP-1 therapy is typically sustained for at least 12 to 24 months for optimal results. A patient on Sequence paying $325 per month for semaglutide spends $3,900 over one year and $7,800 over two years. The same patient on Trimi at $99 per month spends $1,188 per year and $2,376 over two years. The two-year savings of $5,424 represents a meaningful financial difference for most households.
Coaching Models Compared: Behavioral App vs Physician-Led
The most meaningful difference between Noom Med and Sequence is not the medication — it is the support model surrounding it. Noom Med leads with behavioral coaching through a technology-driven app. Sequence leads with physician expertise through a clinician-driven care model. These are fundamentally different philosophies, and understanding them is essential to choosing the right fit.
Noom Med: Behavioral Coaching
Rooted in cognitive behavioral therapy (CBT) principles
App-based daily lessons on food psychology and habit formation
Color-coded food classification system (green, yellow, red)
Daily calorie logging and meal tracking within the Noom app
Group coaching with other Noom users for peer accountability
Goal-setting and progress tracking tools integrated into the app
Focus on changing your psychological relationship with food
Sequence: Physician Oversight
Dedicated physician oversight from obesity medicine specialists
Ongoing clinical monitoring of metabolic markers and progress
Individualized dose titration managed directly by your physician
Clinical support for managing complex side effects and interactions
Medication switching guidance when response plateaus
Lab work coordination and metabolic health tracking
Focus on medical management of obesity as a chronic disease
Noom Med is better suited for patients who want a structured behavioral program that addresses the psychological and habitual dimensions of eating alongside GLP-1 medication. The CBT-based framework is well-designed for patients who struggle with emotional eating, food noise, or difficulty translating nutrition knowledge into daily habits. The app creates a daily engagement loop that some patients find motivating and others find tedious after the first few weeks.
Sequence is better suited for patients who want intensive clinical oversight from a physician who specializes in obesity medicine. For patients with complex medical histories, multiple comorbidities, or concerns about medication interactions, Sequence's physician-first model provides a level of direct medical attention that Noom Med's coaching-first model does not prioritize in the same way. The trade-off is a significantly higher monthly cost.
The premium services question
Both Noom Med and Sequence charge substantial premiums for their respective value-added services. The honest question is whether those services justify an additional $984 to $3,600 per year compared to a medication-focused provider. For the majority of patients with straightforward clinical profiles, the medication produces equivalent weight loss outcomes regardless of the surrounding coaching tier. Patients who are unsure should consider starting with an affordable medication-focused provider and adding coaching or specialist consultations independently if they find they need them.
Clinical Evidence: What Actually Drives Weight Loss
Neither Noom Med nor Sequence has published peer-reviewed clinical trials demonstrating that their specific platform produces outcomes superior to GLP-1 medication with standard clinical oversight. The clinical evidence for GLP-1 weight loss comes from large-scale randomized controlled trials of the medications themselves, not from any individual telehealth platform's coaching methodology or physician oversight model.
Semaglutide: STEP 1 Trial Results
The landmark STEP 1 trial enrolled 1,961 adults and demonstrated that semaglutide 2.4 mg produced an average of 14.9% body weight loss over 68 weeks, compared to 2.4% with placebo. Critically, both groups received lifestyle counseling, meaning the medication — not the counseling — drove the 12.5 percentage point difference (Wilding et al., New England Journal of Medicine, 2021). This is the foundational evidence supporting every semaglutide-based program, whether it is Noom Med, Sequence, or Trimi.
Tirzepatide: SURMOUNT-1 Trial Results
The SURMOUNT-1 trial enrolled 2,539 adults and showed that tirzepatide produced 15% to 20.9% body weight loss over 72 weeks at various doses, compared to 3.1% with placebo. Both groups received lifestyle counseling. The dual GIP/GLP-1 mechanism of tirzepatide produced even greater weight loss than semaglutide alone (Jastreboff et al., New England Journal of Medicine, 2022). Sequence and Trimi both offer tirzepatide. Noom Med's tirzepatide availability has been more limited.
Intensive Coaching vs Standard Counseling
A 2024 study by Wadden et al. in the New England Journal of Medicine compared semaglutide plus intensive behavioral therapy against semaglutide with standard counseling. Both groups lost significant weight, and the intensive therapy group did not demonstrate a clinically meaningful advantage over the standard counseling group. This directly challenges the value proposition of premium coaching programs — including those offered by Noom Med — and suggests that the incremental benefit of premium coaching beyond standard clinical guidance is minimal for most patients.
SELECT Cardiovascular Trial
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity and established cardiovascular disease (Lincoff et al., New England Journal of Medicine, 2023). This cardiovascular benefit is attributable to the medication itself, independent of any coaching methodology or physician oversight model, reinforcing that the pharmacological intervention is the primary therapeutic driver regardless of which platform prescribes it.
The clinical evidence is consistent: GLP-1 medications produce substantial, clinically meaningful weight loss. The medication drives the outcome. Behavioral coaching and premium physician oversight may provide supplementary value for certain patients, but they are not the primary mechanism of weight loss in GLP-1 treatment. This distinction matters because Noom Med charges a premium for coaching and Sequence charges a premium for physician oversight. Patients should decide whether those premiums align with their individual needs and budget, knowing that the medication itself accounts for the vast majority of expected weight loss with any provider.
Who Should Choose Noom Med
Noom Med is the right fit if you specifically want Noom's behavioral psychology approach alongside your GLP-1 medication. Patients who have had success with the Noom app in the past and want to combine that methodology with prescription medication may find value in Noom Med's integrated experience. The CBT-based framework is well-designed for patients who struggle with emotional eating or food psychology and want structured daily guidance through an app they already know and trust.
Noom Med is not the right choice if cost is a significant factor. At $181 to $279 per month effective cost, Noom Med is expensive relative to medication-focused providers, though less expensive than Sequence. The separate medication and app subscriptions can create billing complexity. Patients who are primarily interested in the medication and do not plan to engage deeply with daily app lessons may be paying a substantial premium for features they will not use. If you are currently on Noom Med and looking for alternatives, our guide to canceling Noom Med covers the transition process step by step.
Who Should Choose Sequence
Sequence is the right fit if you have a complex medical history and want the assurance of dedicated physician oversight from an obesity medicine specialist throughout your treatment. Patients with multiple comorbidities, those taking medications with potential GLP-1 interactions, or patients who have struggled with side effect management on other platforms may benefit from Sequence's more intensive clinical model. The physician-led approach provides deeper medical attention than a coaching-first or medication-delivery platform typically offers.
Sequence is not the right choice if affordability is a priority. At $249 to $399 per month for semaglutide and $349 to $399 per month for tirzepatide, Sequence is among the most expensive GLP-1 telehealth options available. Patients with straightforward clinical profiles — those who are overweight but otherwise healthy, without complex medication regimens — are unlikely to derive enough incremental clinical benefit from Sequence's premium physician model to justify the two to four times higher cost compared to medication-focused providers. If you are considering leaving Sequence, our guide to canceling Sequence walks through the process.
Who Should Choose Trimi
Trimi is the right fit if you want effective GLP-1 treatment at the lowest sustainable price without paying for coaching or concierge physician services you may not fully use. Flat pricing, no contracts, no hidden fees, and responsive clinical support make Trimi the most financially straightforward option. Access to both semaglutide and tirzepatide at dose-independent pricing means your cost never increases as your treatment progresses through the titration schedule.
Trimi is not the right choice if you specifically want intensive app-based behavioral coaching (Noom Med) or dedicated obesity medicine specialist oversight (Sequence). Trimi's model focuses on competent clinical medication management rather than comprehensive behavioral programming or premium physician concierge services. The trade-off is clear: patients who choose Trimi save $984 to $3,600 annually but forgo the supplementary platforms that Noom Med and Sequence provide. For patients who are self-motivated or prefer to manage their own nutrition and exercise alongside GLP-1 medication, this trade-off strongly favors Trimi.
The Bottom Line
The medication drives the clinical outcome, regardless of provider
GLP-1 medication is the primary cause of weight loss across all three programs. The STEP 1 trial demonstrated 14.9% weight loss with semaglutide and the SURMOUNT-1 trial showed up to 20.9% with tirzepatide. When you pay more at Noom Med or Sequence, you are paying for coaching or physician concierge services, not for a pharmacologically superior treatment. The medication is the same.
Sequence costs the most, Noom Med sits in the middle, Trimi costs the least
For semaglutide over twelve months: Sequence totals $2,988 to $4,788, Noom Med totals $2,172 to $3,348, and Trimi totals $1,188. The annual savings of $984 to $3,600 by choosing Trimi are substantial, especially for a treatment that most patients sustain for at least 12 to 24 months.
Start with the medication, add premium services if you need them
Rather than starting with an expensive coaching-plus-medication or physician-concierge program and downgrading later, consider starting with a cost-effective medication provider like Trimi. If you find you need additional behavioral support or specialist physician oversight after beginning treatment, standalone coaching apps and obesity medicine consultations are available independently, often at lower cost than the premiums charged by Noom Med or Sequence.
Frequently Asked Questions
Is Noom Med the same as regular Noom?
No. Regular Noom is a behavioral weight loss app that uses cognitive behavioral therapy techniques without medication. Noom Med is a separate clinical program that pairs GLP-1 medications such as semaglutide with Noom's app-based coaching. Noom Med requires a medical evaluation and prescription. The Noom Med subscription covers medication and clinical oversight, but the Noom app subscription may be an additional $32 to $70 per month unless bundled into a combined plan.
Does Sequence prescribe tirzepatide?
Yes. Sequence offers both semaglutide and tirzepatide as part of its GLP-1 weight loss program. Tirzepatide through Sequence costs approximately $349 to $399 per month. For comparison, Trimi offers tirzepatide at $125 per month with flat pricing regardless of dose, saving patients $224 to $274 per month on tirzepatide alone.
Which is cheaper, Noom Med or Sequence?
Noom Med is less expensive than Sequence for semaglutide. Noom Med charges $149 to $209 per month for the medication subscription, with a possible additional Noom app fee of $32 to $70 per month. Sequence charges $249 to $399 per month for semaglutide with physician oversight included. However, both are substantially more expensive than medication-focused providers like Trimi, which charges $99 per month for semaglutide with all clinical services included.
Do I need premium coaching to lose weight on GLP-1 medication?
Clinical evidence indicates that GLP-1 medication is the primary driver of weight loss. The STEP 1 trial demonstrated 14.9 percent body weight loss with semaglutide compared to 2.4 percent with placebo, and coaching was provided to both groups (Wilding et al., NEJM, 2021). A 2024 study by Wadden et al. found that intensive behavioral therapy alongside semaglutide did not produce a clinically meaningful advantage over standard counseling. Many patients achieve excellent results with medication and standard clinical oversight alone, without premium coaching or concierge physician programs.
Can I switch from Noom Med or Sequence to a cheaper provider?
Yes. Switching from Noom Med or Sequence to another GLP-1 provider is straightforward. Your medication type and current dose transfer without interruption. The main consideration is timing the switch to avoid a gap in your medication supply. Review any contract terms or cancellation policies before switching. Detailed guides are available for canceling Noom Med and canceling Sequence.
Is Sequence worth the higher price compared to Noom Med?
Sequence's higher price reflects its emphasis on dedicated physician oversight by obesity medicine specialists, which goes beyond the coaching-plus-prescriber model that Noom Med uses. Whether this is worth the premium depends on your clinical complexity. Patients with multiple comorbidities or complex medication interactions may benefit from Sequence's physician-intensive approach. Patients with straightforward clinical profiles often find that standard clinical oversight — available at a fraction of the cost through providers like Trimi — produces equivalent weight loss outcomes.
What happens if I stop paying for coaching or physician concierge services but want to keep my medication?
If you stop your Noom Med or Sequence subscription, you lose access to both the platform services and your medication prescription. These programs bundle their value-added services with medication access, so you cannot keep one without the other. To continue GLP-1 treatment without coaching or concierge fees, you would need to transfer your care to a medication-focused provider like Trimi, which charges $99 per month for semaglutide with clinical oversight included.
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
- Wadden TA, et al. Intensive behavioral therapy and semaglutide for obesity. N Engl J Med. 2024.
- Noom Health, Inc. Noom Med official program and pricing information. 2026.
- Sequence Health, Inc. Sequence official program and pricing information. 2026.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Individual results vary. Trimi is a competing provider; this comparison is presented fairly but readers should verify current pricing and program details directly with each provider. Pricing information reflects publicly available data as of April 2026 and is subject to change.